Pharmacy Drugs
Recent Posts
- Malignant Brain Tumors: Chemotherapy Alone Is Just As Effective As Radiation / New Positive Prognostic Factor Found
- Positive Interim Data From Minnow Medical Peripheral Artery Disease Trial Presented At TCT 2009 Conference
- Intercept Pharmaceuticals’ FXR Agonist INT-747 Meets Primary Endpoint In A Phase II Clinical Trial In Type 2 Diabetic Patients
- Largest Clinical Trial To Test Benefits Of Aspirin In Australia
- University Of Florida To Receive $29.5 Million In Recovery Act Funds To Begin Study Of Whether Exercise Prevents Disability In Older Adults
Random Posts
- UT Southwestern Researchers Find Participants In Antidepressant Drug Trials Are Atypical Patients
- APhA Seeks Nominations For Scientific Awards And Honors
- PHT Corporation's Market Leading LogPad And StudyWorksTM EPRO Solutions Used In Sanofi Pasteur's Phase II Study Of New Clostridium Difficile Vaccine
- ThromboGenics And BioInvent Start Recruitment Of Second 100 Patient Cohort In Phase II DVT Prophylaxis Study With TB-402
- DaVita Study Demonstrates Clinical Application Of Sysmex Reticulocyte Hemoglobin Equivalent (RET-He) Parameter
- Link Between Vitamin D And Reduction In Multiple Sclerosis Risk
- Minimally Invasive Stent Treatment Aids Chronic Venous Insufficiency
- Sinovac Files Clinical Trial Application With SFDA For Vaccine Against Hand, Foot, And Mouth Disease
- New Tests For Identifying Potentially Deadly Adulterants In Pharmaceutical Ingredients
- Disclosing Your Feelings May Help The Course Of Rheumatoid Arthritis: Results From A Randomized Clinical Trial
Versartis Presents Preclinical Data For Novel Type 2 Diabetes Drug
Posted by: admin in Pharmacy Drugs on September 30th, 2009
Versartis, Inc. today presented preclinical data demonstrating the potential for monthly dosing of its lead product, VRS-859 (exenatide-XTEN), for the treatment of type 2 diabetes. The data were presented by Jeffrey Cleland, Ph.D., Founder and Chief Executive Officer of Versartis, at the IBC Protein Engineering & Design Conference in San Diego.
In his talk, “Half-life Extension and In Vivo Biological Activity of Peptide and Protein Therapeutics,” Dr. Cleland presented VRS-859 preclinical data in models of diabetes and pharmacokinetics in mice, rats, dogs and monkeys. Versartis has begun development activities for VRS-859 including manufacturing and regulatory meetings. A clinical study of VRS-859 in patients with type 2 diabetes is planned for the first half of 2010.
Versartis is also finalizing lead selection for VRS-317 (human growth hormone-XTEN), a monthly dosage form. Dr. Cleland presented preclinical proof of concept and pharmacokinetic data. Versartis plans to begin Phase I clinical trials of VRS-317 in patients with growth hormone deficiency in the second half of 2010.
In addition to the reduced dosing frequency, Versartis’ XTEN products enable room temperature stability and low cost manufacturing. The XTEN properties allow for co-formulation and co-administration of proteins and peptides that are normally incompatible. Versartis is conducting research on combination products for metabolic disease to exploit these novel properties.
“Versartis is focusing on treatments for metabolic and endocrine diseases that currently require daily or weekly dosing,” explained Dr. Cleland. “Our results to date demonstrate the potential for monthly dosing of our compounds. The potential for improved convenience along with other XTEN properties provide a distinct advantage for Versartis’ products over other products on the market or in development.”
Source
Versartis, Inc.
No Comments »
No comments yet.
RSS feed for comments on this post. TrackBack URL
Leave a comment
You must be logged in to post a comment.